1. Home
  2. ALKS

as of 07-20-2026 3:46pm EST

$52.16
$0.56
-1.06%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Founded: 1987 Country:
Ireland
Ireland
Employees: N/A City: DUBLIN 4
Market Cap: 8.7B IPO Year: 2012
Target Price: $43.43 AVG Volume (30 days): 2.3M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.40 EPS Growth: -34.10
52 Week Low/High: $25.16 - $55.67 Next Earning Date: 05-05-2026
Revenue: $1,475,899,000 Revenue Growth: -5.25%
Revenue Growth (this year): 24.26% Revenue Growth (next year): 4.47%
P/E Ratio: -131.57 Index: N/A
Free Cash Flow: 480.3M FCF Growth: +18.41%

AI-Powered ALKS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 76.11%
76.11%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Alkermes plc (ALKS)

Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Sell
ALKS Jul 6, 2026

Avg Cost/Share

$54.03

Shares

2,034

Total Value

$109,897.02

Owned After

227,490

SEC Form 4

Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Sell
ALKS Jul 1, 2026

Avg Cost/Share

$51.80

Shares

9,000

Total Value

$463,620.77

Owned After

74,089

Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Sell
ALKS Jun 4, 2026

Avg Cost/Share

$43.05

Shares

2,034

Total Value

$87,563.70

Owned After

227,490

SEC Form 4

Hopkinson Craig C.

EVP R&D, Chief Medical Officer

Sell
ALKS Jun 1, 2026

Avg Cost/Share

$41.67

Shares

9,000

Total Value

$375,043.50

Owned After

74,089

SEC Form 4

Parisi Samuel Joseph

VP, Finance (Interim PAO)

Sell
ALKS May 29, 2026

Avg Cost/Share

$42.36

Shares

16,217

Total Value

$687,007.26

Owned After

7,717

SEC Form 4

Gaffin David Joseph

EVP, CLO, Alkermes, Inc.

Sell
ALKS May 4, 2026

Avg Cost/Share

$33.20

Shares

2,034

Total Value

$67,528.80

Owned After

227,490

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q1

Q1 2026 Earnings

8-K BUY

May 5, 2026 · 100% conf.

AI Prediction BUY

1D

+1.70%

$36.87

Act: -2.57%

5D

+3.70%

$37.59

Act: +5.63%

20D

+4.28%

$37.80

Act: +17.96%

Price: $36.25 Prob +5D: 100% AUC: 1.000
0001193125-26-205008

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784470094.ec62c2a1

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2025
Q4

Q4 2025 Earnings

8-K SELL

Feb 25, 2026 · 86% conf.

AI Prediction SELL

1D

+0.05%

$31.05

Act: -1.00%

5D

-4.06%

$29.78

Act: -5.67%

20D

-3.04%

$30.10

Price: $31.04 Prob +5D: 7% AUC: 1.000
0001193125-26-068512

8-K

0001520262falseAlkermes plc.00015202622026-02-252026-02-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 25, 2026

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland

001-35299

98-1007018

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

Registrant's telephone number, including area code: + 353-1-772-8000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary shares, $0.01 par value

ALKS

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 25, 2026, Alkermes plc (the “Company”) announced financial results for the three months and year ended December 31, 2025 and financial expectations for the year ending December 31, 2026. Copies of the related press release and the investor presentation to be displayed during the Company’s conference call on February 25, 2026 discussing such financial results and expectations are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. This information, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits

EXHIBIT INDEX

Exhibit No.

Description

99.1

Press release issued by Alkermes plc on February 25, 2026 announcing financial results for the three months and year ended December 31, 2025 and financial expectations for the year ending December 31, 2026.

99.2

Investor presentation to be displayed by Alkermes plc on February 25, 2026.

104

Cover page interactive data file (embedded within the Inline XBRL document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALKERMES PLC

Date: February 25, 2026

By:

/s/ Joshua Reed

Joshua Reed

Senior Vice President, Chief Financial Officer (Principal Financial Officer)

3

2025
Q4

Q4 2025 Earnings

8-K SELL

Jan 12, 2026 · 86% conf.

AI Prediction SELL

1D

+0.05%

$31.05

Act: -1.00%

5D

-4.06%

$29.78

Act: -5.67%

20D

-3.04%

$30.10

Price: $31.04 Prob +5D: 7% AUC: 1.000
0001193125-26-009813

8-K

0001520262FalseAlkermes plc.00015202622026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 12, 2026

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

Ireland

001-35299

98-1007018

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

Connaught House, 1 Burlington Road

Dublin 4, Ireland D04 C5Y6

(Address of principal executive offices)

Registrant's telephone number, including area code: + 353-1-772-8000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary shares, $0.01 par value

ALKS

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Conditions.

On January 12, 2026, Alkermes plc (the “Company”) made available a copy of the corporate presentation to be displayed during its presentation at the J.P. Morgan Healthcare Conference on January 13, 2026, which includes the Company’s estimated total revenues for the year ended December 31, 2025, which are preliminary, unaudited and subject to change upon completion of the Company’s review of its financial statements for the year ended December 31, 2025. A copy of the presentation is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

The information in Item 2.02 above and in Exhibit 99.1 furnished herewith are incorporated in this Item 7.01 by reference.

The information contained in this Form 8-K, including in Items 2.02 and 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits

EXHIBIT INDEX

Exhibit No.

Description

99.1

Alkermes plc corporate presentation.

104

Cover page interactive data file (embedded within the Inline XBRL document).

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALKERMES PLC

Date: January 12, 2026

By:

/s/ David J. Gaffin

David J. Gaffin

Secretary

3

Share on Social Networks: